India: India’s Patents Bill, 2005 - Is It TRIPS Compliant?

Last Updated: 31 March 2005
Article by Manoj Pillai

Finally, the Indian Parliament passed the Patents Bill (Bill No. 32-C of 2005). The Bill replaces the Patents Ordinance, 2004. For the first time in independent India’s history, national newspapers carried 4-column headline news covering ‘patents’. Patents Bill was also the topic of prime-time news in national TV channels. The ‘news value’ of the patents amendment bill was because of the political color it acquired. The Ordinance was strongly criticized by the Left Parties. The Patents Bill to substitute the Ordinance, therefore, created a national uproar. Finally, with several amendments mooted reportedly by the Left Parties, the Bill is passed. These amendments have considerably diluted the Ordinance. On a preliminary reading, the Bill (as passed) seems to fall short of TRIPS compliance. This memo highlights the major differences between the Ordinance and the Patents (Amendment) Bill, 2005 (hereinafter ‘the Bill’) and also enquires if it is TRIPS compliant!

The Bill redefines "inventive step"!

A new section 2(1)(ja) substituted the existing definition of ‘inventive step’ to mean "a feature of an invention that involves technical advances as compared to the existing knowledge or having economic significance or both and that makes the invention not obvious to a person skilled in the art".

This is an interesting attempt to ‘redefine’ one of the cardinal patentability criteria. ‘Inventive Step’ was originally defined in the Act to mean ‘a feature that makes the invention not obvious to a person skilled in the art’. An Explanatory note to Art. 27 (1) of the TRIPS Agreement states that ‘inventive step’ is synonymous with ‘non-obviousness’. There exists a plethora of judicial pronouncements on what constitute ‘non-obviousness’ as a criterion of patentability. Further, many national patent offices have practice guidelines explaining the fundamental propositions concerning what is not obvious to a ‘person of ordinary skill’ in a given technological art – so as to make an invention patentable.

The new wording of this Section does not reflect the distilled stock of knowledge on this subject. The wording ‘technical advances as compared to existing knowledge’ rather dilutes the very basis of obviousness/novelty requirements. If an invention is not adequately distinctive over prior art – it is not patentable. As such, what is the additional safeguard achieved by adding expressions that have the scope to make the whole definition vague and arbitrary?

The second phrase is ‘economic significance’. An invention to be non-obvious has to have ‘economic significance’ or ‘technical advances as compared to existing knowledge’! If so, what is the very purpose of the ‘utility’ criterion for patentability? By bringing ‘economic significance’ under the definition of ‘non-obviousness’ what has been fundamentally diluted is a cardinal principle of patent law! This new definition defeats the objectives behind the amendment. It interferes with the time-tested principles of patents law, and in that process has created a new definition that can lead to loose interpretations. It indeed falls short of the international legal practices on patentability – And arguably it is TRIPS non-compliant.

A new definition for ‘new inventions’

Unprecedented it is. The Bill retains the old definition of ‘invention’ in Section 2(1)(j). It however, added a definition on ‘new invention’. ‘New invention’ means any invention or technology which has not been anticipated by publication in any document or used in the country or elsewhere in the world before the date of filing of a patent application with complete specification, i.e. the subject matter has not fallen in public domain or that it does not form part of the state of the art.

Now the central question is this – whether the aforesaid definition of ‘new invention’ is an additional limitation on the definition of ‘invention’ under Section 2(1)(j). And if it is, does this amendment conform to Art. 27 of the TRIPS Agreement?

Here again, one can see a fundamental dilution of the tested principles of patent law. ‘Novelty’ of an invention is typically ascertained by testing if the invention has been anticipated by prior publication, or prior public working or prior public knowledge. There exists a huge stock of case laws on this. There are ways to ascertain this as well – of course with some levels of inherent limitations in carrying out prior art searches. But, redefining the ‘novelty’ requirement in the manner provided in the Bill deviates from the foundational norms on the test of novelty (to in turn ascertain patentability). This is another amendment that takes this Bill far away from the TRIPS Agreement. It puts unreasonable burden on a patent applicant to substantiate the novelty (and consequently patentability) of the claimed invention.

New Use – Redefined

The Ordinance amended Section 3(d) to ensure that what is not patentable is only mere new use. If a second medical indication of a known drug molecule passes the test that it is not a mere new use – as per the Ordinance it would have been patentable. The Bill drops this provision. Instead, it contains a rather too long explanation on the Section 3(d) exemption. According to this Section what is not patentable is:

"The mere discovery of a new form of a known substance which does not result in the enhancement of the known efficacy of that substance"

"The mere discovery of any new property or new use for a known substance"

"The mere use of a known process, machine or apparatus – unless such process results in a new product or employs at least one new reactant"

Consequently, if a discovery of a new form of a known drug molecule (as for example) results in an enhancement of its known efficacy, it is patentable. Similarly, the mere discovery of a new use of a known substance is not patentable. The amended Section 3(d) when read in conjunction with Section 3(i) would ensure that all method of use inventions are unpatentable. A joint reading of the amended Section 3(d) and Section 3(i) is capable of keeping a major portion of pharmaceutical R&D outside the scope of patents.

The Bill provides an explanation that salts, esters, ethers, polymorphs, metabolites, pure form, particle size, isomers, mixtures of isomers, complexes, combinations and other derivatives of known substance shall be considered to be the same substance, unless they differ significantly in properties with regard to efficacy. The phrase ‘differ significantly in properties with regard to efficacy’ is the final test of patentability as regards all inventions around a drug molecule. It seems this Explanation will keep a huge amount of research and development activity outside the scope of patentability – because the properties concerning efficacy (according to the Bill) will have an overriding effect over the standard tests of patentability when it comes to pharmaceutical inventions.

The objective behind such an elaborate explanation in Section 3(d) seems to be to check what the Indian generic drug makers allege as ‘evergreening’. However, this exclusion also seems to result in nonconformity of the amended law with the general mandate on patentability provided in the TRIPS Agreement.

Software Patents – new provision dropped

The Bill dropped the amendments to Section 3(k) as contained in the Ordinance. The Ordinance had introduced a new Section 3(ka) to exclude ‘mathematical methods, business methods or algorithms’ from the scope of patentability. As per Section 3(k) (as contained in the Ordinance) a computer program’s technical application to industry or a computer program in combination with hardware was patentable. What was not patentable was only computer program per se.

The Ordinance attempted to strike a balance between the arguments for and against software patents. It indeed brought the position close to the European Patent Office practices. That was a welcome change. Conventionally, there has been an argument in India that copyright is a preferred mode to protect computer software. That kept a huge amount of R&D activities involving computer software outside the scope of patents. India’s leading IT companies and industry associations favored a reasonable level of protection of computer software through patents. The Bill deviated from the Ordinance and brought back the original position. Now what is patentable in this area is – what is not computer program per se.

Mail Box Application can lead only to ‘Paper Patents’!

A Patent acquired through the Mail Box route is virtually of no use. The Bill says that a patentee who gets a patent through the Mail Box cannot institute infringement action against any enterprise that has been producing and marketing the patented product prior to January 1, 2005 and continues to manufacture the product as on the date of grant of the patent. Therefore a pharmaceutical company that has filed a patent application through the Mail Box route when eventually gets a patent for its product, it cannot file an infringement action against an Indian generic manufacturer who continues to manufacture the patented product. All what the patentee-company can ask for is ‘reasonable’ royalty! This provision takes away the very sanctity of Mail Box and transitional protection as envisaged in the TRIPS Agreement.

The above provision can be found in the newly inserted 3rd proviso to Section 11A. It is one of the amendments mooted during the recent political deliberations. This proviso undermines the whole concept of transitional protection under the TRIPS Agreement and definitely makes the Bill TRIPS non-compliant.

No More Representation – It is Opposition Before & After the Grant!

All grounds available for post-grant opposition have been made available to pre-grant opposition as well. The Bill thus envisages 2 oppositions! – First when the application is published, and second when a patent is granted. The post-grant opposition has to be initiated by an ‘interested person’. But any person can institute pre-grant opposition with the same ground as that of the post –grant opposition!

Interestingly the law allows a pre-grant opponent the right to be heard! There is, however, no provision in the Bill enabling the Applicant to counter the pre-grant opposition. That alone makes it a one-sided affair.

It is pertinent to highlight that the Rules framed under the Ordinance even mandated that the Pre-grant opponent has to file ‘a statement supported by evidence’. That made the pre-grant opposition a legal proceeding involving a process of adducing evidence. In a proceeding when the Opponent is allowed to adduce evidence against the patent applicant and if the patent applicant is given no chance to counter the evidence, it violates the fundamentals of administrative law & justice. That can possibly make this provision arbitrary and hence unconstitutional. Accordingly, the pre-grant opposition provision, which does not give the Patent Applicant the right to counter evidence adduced against him, may not stand the test of judicial scrutiny.

Compulsory License – grounds further expanded

The already elaborate Compulsory Licensing grounds got another boost. The newly inserted Section 92A(1) of the Bill expanded the scope of issuance of Compulsory Licenses for manufacture and export of patented pharmaceutical products to countries having insufficient manufacturing capacity in the pharmaceutical sector, if that country has by notification allowed such importation.

Concluding Remarks

As on date is the Indian Patents Act, 1970 (as amended by the Patents (Amendment) Bill, 2005 TRIPS complaint? This is the million-dollar question! While there cannot be a final answer to this until competent bodies address and decide on it, there are reasons to consider that it in fact is not TRIPS compliant. It has been reported in the national dailies that the Government will seek expert opinion on some issues pertaining to patentable subject matters. If so, presumably the final TRIPS compliance is yet to happen. It is time to wait and watch how the International community responds to India’s latest attempt on TRIPS compliance.

© Lex Orbis 2005

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions